Arthritis Drug May Treat Dry Eye Disease

Published Online: Friday, May 17, 2013
Follow Pharmacy_Times:
Topical anakinra, a drug used to treat rheumatoid arthritis, may be a safe and effective treatment for dry eye disease, according to a recent study published online by JAMA Ophthalmology on April 18, 2013.

Researchers from the Massachusetts Eye and Ear Infirmary, Harvard Medical School, and Brigham and Women’s Hospital conducted a 16-week random, double-blind study to assess the effectiveness of topical anakinra in 75 patients diagnosed with dry eye disease. Participants were selected to receive eye lubricant, 2.5% of anakinra, or 5% of anakinra.

After 12 weeks of treatment, patients receiving 2.5% anakinra saw a 46% reduction of corneal staining and a 30% decrease in their overall dry eye symptoms. The drug, in either dosage, was 6 times more effective in treating symptoms than the eye lubricant. The researchers also found that patients who stopped taking anakinra at 12 weeks had worsened symptoms by the end of the study. The participants tolerated the drug and none experienced serious side effects.

“We have never seen results such as this before in a trial to treat dry eye disease,” said lead author Reza Dana, MD, MSc, MPH, in a press release. “We possibly have found a safe, well-tolerated eye drop that an treat the underlying cause of dry eye rather than just temporarily mask the symptoms.”

Related Articles
Shire plc has submitted a New Drug Application to the FDA for its investigational compound designed to treat patients with dry eye disease.
Lilly and Incyte have recently announced positive results from the second phase 3 study of their investigational drug baricitinib, a potential treatment for rheumatoid arthritis.
Patients with celiac disease are known to be deficient in the amino acid L-carnitine, a nutrient essential for muscle energy production.
Amgen has announced positive results of a phase 3 study evaluating its investigational drug, ABP 501, a biosimilar candidate to AbbVie’s fully human anti-tumor necrosis factor alpha monoclonal antibody, adalimumab, in patients with moderate-to-severe rheumatoid arthritis.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times